[HTML][HTML] A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naive metastatic non-small cell lung cancer
SK Padda, KL Reckamp, M Koczywas, JW Neal… - Cancer chemotherapy …, 2022 - Springer
… upfront treatment of advanced epidermal growth factor … erlotinib’s toxicities of rash and
diarrhea onset in the first 2–3 weeks of treatment [29] allowing for (i) dose adjustment for erlotinib-…
diarrhea onset in the first 2–3 weeks of treatment [29] allowing for (i) dose adjustment for erlotinib-…
[HTML][HTML] Targeting epidermal growth factor receptor by MiRNA-145 inhibits cell growth and sensitizes NSCLC cells to Erlotinib
J Amri, N Molaee, M Baazm… - Asian Pacific Journal of …, 2019 - ncbi.nlm.nih.gov
… The results showed that single treatment with erlotinib induced cytotoxicity in a dose-dependent
way. At 24 and 48 h after transfection, miRNA-145 alone significantly decreased the cell …
way. At 24 and 48 h after transfection, miRNA-145 alone significantly decreased the cell …
[HTML][HTML] KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene
MS Roberts, LJ Anstine, VS Finke, BL Bryson… - Breast Cancer …, 2020 - Springer
… not display amplification of the human epidermal growth factor receptor 2 (HER2) gene. …
treatment for TNBC. In 2019, atezolizumab, a PD-L1 inhibitor, was approved for the treatment of …
treatment for TNBC. In 2019, atezolizumab, a PD-L1 inhibitor, was approved for the treatment of …
First-line angiogenesis inhibitor plus erlotinib versus erlotinib alone for advanced non-small-cell lung cancer harboring an EGFR mutation
T Landre, G Des Guetz, K Chouahnia… - Journal of Cancer …, 2020 - Springer
… growth factor (VEGF) inhibitor (anti-VEGF) in combination with the tyrosine-kinase
inhibitor erlotinib … first-line erlotinib + anti-VEGF compared to erlotinib alone to treat EGFR-mutated …
inhibitor erlotinib … first-line erlotinib + anti-VEGF compared to erlotinib alone to treat EGFR-mutated …
EGFR inhibitor erlotinib plus monoclonal antibody versus erlotinib alone for first-line treatment of advanced non-small cell lung carcinoma: A systematic review and …
M Liu, K Xiao, L Yang - International Immunopharmacology, 2023 - Elsevier
… The epidermal growth factor receptor (EGFR) gene regulates the growth, differentiation,
survival, and metastasis of tumor cells, and approximately 40% to 89% of NSCLC patients have …
survival, and metastasis of tumor cells, and approximately 40% to 89% of NSCLC patients have …
… , erlotinib, and gemcitabine versus erlotinib and gemcitabine in patients with untreated, metastatic pancreatic adenocarcinoma: North Central Cancer Treatment Group …
TR Halfdanarson, NR Foster, GP Kim, JP Meyers… - The …, 2019 - academic.oup.com
… Dual epidermal growth factor receptor (EGFR)‐directed therapy with erlotinib and
panitumumab in combination with gemcitabine was superior to gemcitabine and erlotinib, but the …
panitumumab in combination with gemcitabine was superior to gemcitabine and erlotinib, but the …
[HTML][HTML] EGFR signaling is overactive in pachyonychia congenita: effective treatment with oral erlotinib
J Basset, L Marchal, A Hovnanian - Journal of Investigative Dermatology, 2023 - Elsevier
… for which there is no standard current treatment. PC is caused by dominant mutations in …
, we treated three patients with PC with oral erlotinib for 6‒8 months. The treatment was well…
, we treated three patients with PC with oral erlotinib for 6‒8 months. The treatment was well…
Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and …
YI Zhao, J Liu, X Cai, Z Pan, J Liu, W Yin, H Chen, Z Xie… - Bmj, 2019 - bmj.com
… If necessary, we used the reported ratio of erlotinib versus gefitinib (34%;66%) in the control
… of other treatments to an EGFRTKI, such as erlotinib plus bevacizumab versus erlotinib (…
… of other treatments to an EGFRTKI, such as erlotinib plus bevacizumab versus erlotinib (…
[HTML][HTML] Efficacy and safety of epidermal growth factor receptor (EGFR) inhibitors plus antiangiogenic agents as first-line treatments for patients with advanced EGFR …
F Chen, N Chen, Y Yu, J Cui - Frontiers in Oncology, 2020 - frontiersin.org
… Hypoxia-driven vascular endothelial growth factor (VEGF) is a … to the vascular endothelial
growth factor receptor (VEGFR) (11)… benefit from erlotinib plus anti-VEGF therapy than erlotinib …
growth factor receptor (VEGFR) (11)… benefit from erlotinib plus anti-VEGF therapy than erlotinib …
Substance P receptor blocker, aprepitant, inhibited cutaneous and other neurogenic inflammation side effects of the EGFR1-TKI, erlotinib
JJ Chmielinska, JH Kramer, IT Mak, CF Spurney… - Molecular and Cellular …, 2020 - Springer
… treatment with the epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI),
erlotinib. … impair the patient’s compliance with the treatment or even cause its discontinuation. In …
erlotinib. … impair the patient’s compliance with the treatment or even cause its discontinuation. In …